Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.17 - $8.05 $49,135 - $124,775
15,500 Added 135.96%
26,900 $114,000
Q1 2024

May 15, 2024

BUY
$4.07 - $8.68 $11,396 - $24,304
2,800 Added 32.56%
11,400 $82,000
Q4 2023

Feb 14, 2024

BUY
$3.71 - $5.14 $31,906 - $44,204
8,600 New
8,600 $43,000

Others Institutions Holding ABEO

About ABEONA THERAPEUTICS INC.


  • Ticker ABEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,950,380
  • Market Cap $33.5M
  • Description
  • Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...
More about ABEO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.